<DOC>
	<DOC>NCT00002064</DOC>
	<brief_summary>To compare pyrimethamine and intravenous (IV) clindamycin vs. pyrimethamine and sulfonamides in the treatment of AIDS patients with central nervous system (CNS) Toxoplasma gondii.</brief_summary>
	<brief_title>Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Toxoplasmosis</mesh_term>
	<mesh_term>Toxoplasmosis, Cerebral</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<criteria>Exclusion Criteria Coexisting Condition: Patients with the following conditions are excluded: Opportunistic infection (Pneumocystis carinii pneumonia (PCP), cryptococcal meningitis) or other conditions (brain abscess) which would make treatment results difficult to interpret due to concurrent infection, disease, or therapy. Patients with other opportunistic infections or brain diseases are excluded. Patients with AIDS and cerebral toxoplasmosis.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 1989</verification_date>
	<keyword>Sulfonamides</keyword>
	<keyword>Toxoplasmosis</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Pyrimethamine</keyword>
	<keyword>Drug Therapy, Combination</keyword>
	<keyword>Encephalitis</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Clindamycin</keyword>
</DOC>